Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice
- 56 Downloads
Enterovirus 71 (EV71) is the major causative agent of hand-foot-and-mouth disease (HFMD) and many neurological manifestations. Recently, this virus has become a serious concern because of consecutive epidemics in the Asia-Pacific region. However, no effective vaccine for EV71 has been discovered except two EV71 vaccines which are being used in local communities of China. To develop a safe and efficient EV71 vaccine candidate, we generated inactivated EV71 and evaluated its efficacy with γ-PGA/Chitosan nanoparticles (PC NPs), which are safe, biodegradable and effective as an adjuvant. The subcutaneous administration of inactivated EV71 with PC NPs adjuvant induces higher levels of virus-specific humoral (IgG, IgG1, and IgG2a) and cell-mediated immune responses (IFN-γ and IL-4). Additionally, inactivated EV71 with PC NPs adjuvant induces significantly higher virus neutralizing antibody responses compared to the virus only group, and resulted in a long lasting immunity without any noticeable side effects. Together, our findings demonstrate that PC NPs are safe and effective immunogenic adjuvants which may be promising candidates in the development of more efficacious EV71 vaccines.
This work was supported by Chungnam National University
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants by any of the authors. All animal experiments were conducted strictly in accordance with Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) with the approval of Institutional Animal Care and Use committee of Bioleaders Corporation, Daejeon, South Korea. (reference number: BSL-ABSL-14-000).
- 12.Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81:9386–9395CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Chen HF, Chang MH, Chiang BL, Jeng ST (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24:944–2951Google Scholar
- 26.Kim S, Yang JY, Lee K, Oh KH, Gi M, Kim JM, Paik DJ, Hong S, Youn J (2009) Bacillus subtilis-specific poly-gamma-glutamic acid regulates development pathways of naive CD4(+) T cells through antigen-presenting cell-dependent and -independent mechanisms. Int Immunol 21:977–990CrossRefPubMedGoogle Scholar
- 27.Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ (2012) Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol 160:277–289CrossRefPubMedGoogle Scholar
- 28.Chowdhury MY, Kim TH, Uddin MB, Kim JH, Hewawaduge CY, Ferdowshi Z, Sung MH, Kim CJ, Lee JS (2017) Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes. Vet Microbiol 201:240–251CrossRefPubMedGoogle Scholar
- 46.Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L (1998) Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16:2039–2046CrossRefPubMedGoogle Scholar
- 48.Duque GA, Descoteaux A (2014) Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 5:491Google Scholar
- 52.Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y et al (2007) Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25(49):8270–8278CrossRefPubMedGoogle Scholar
- 54.Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, Li XF, Deng YQ, Zhu SY, Wang XY, Lin F, Zhang FJ, Chen W, Qin ED, Qin CF (2013) Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 8:e64024CrossRefPubMedPubMedCentralGoogle Scholar